Gene Therapy in Heart Failure : SERCA2a as a Therapeutic Target

DOI Web Site Web Site PubMed 被引用文献1件 参考文献51件
  • Hayward Carl
    NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital National Heart & Lung Institute, Imperial College London
  • Patel Hitesh
    NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital National Heart & Lung Institute, Imperial College London
  • Lyon Alexander
    NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital National Heart & Lung Institute, Imperial College London

書誌事項

タイトル別名
  • Gene Therapy in Heart Failure
  • – SERCA2a as a Therapeutic Target –

この論文をさがす

抄録

The treatment of heart failure (HF) may be entering a new era with clinical trials currently assessing the value of gene therapy as a novel therapeutic strategy. If these trials demonstrate efficacy then a new avenue of potential treatments could become available to the clinicians treating HF. In principle, gene therapy allows us to directly target the underlying molecular abnormalities seen in the failing myocyte. In this review we discuss the fundamentals of gene therapy and the challenges of delivering it to patients with HF. The molecular abnormalities underlying HF are discussed along with potential targets for gene therapy, focusing on SERCA2a. We discuss the laboratory and early clinical evidence for the benefit of SERCA2a gene therapy in HF. Finally, we discuss the ongoing clinical trials of SERCA2a gene therapy and possible future directions for this treatment. (Circ J 2014; 78: 2577–2587)

収録刊行物

  • Circulation Journal

    Circulation Journal 78 (11), 2577-2587, 2014

    一般社団法人 日本循環器学会

被引用文献 (1)*注記

もっと見る

参考文献 (51)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ